$1.32
0.38%
Nasdaq, Apr 21, 09:18 pm CET
ISIN
US81642T1007
Symbol
SLS
Sector
Industry

SELLAS Life Sciences Group, Inc. Stock price

$1.31
+0.18 15.93% 1M
+0.06 4.80% 6M
+0.27 25.96% YTD
-0.10 7.09% 1Y
-2.10 61.58% 3Y
-0.41 23.84% 5Y
-41,998.69 100.00% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.03 2.34%
ISIN
US81642T1007
Symbol
SLS
Sector
Industry

Key metrics

Market capitalization $119.01m
Enterprise Value $106.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 10.24
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-31.51m
Free Cash Flow (TTM) Free Cash Flow $-35.40m
Cash position $13.99m
EPS (TTM) EPS $-0.54
P/E forward negative
Short interest 9.01%
Show more

Is SELLAS Life Sciences Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

SELLAS Life Sciences Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

Buy
100%

Financial data from SELLAS Life Sciences Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
7% 7%
-
- Research and Development Expense 19 19
20% 20%
-
-32 -32
16% 16%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -32 -32
17% 17%
-
Net Profit -31 -31
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about SELLAS Life Sciences Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SELLAS Life Sciences Group, Inc. Stock News

Neutral
GlobeNewsWire
13 days ago
- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months -
Neutral
Seeking Alpha
21 days ago
Sellas Life Sciences Group, Inc.'s stock has dropped significantly, with a Hold rating due to uncertainty around the final Phase 3 trial data for GPS in AML. Interim results for GPS are promising but inconclusive; the trial continues until 80 patients die, creating investment uncertainty and ongoing cash burn. The company raised $25M in January 2025, extending its runway to late 2025, but may n...
Neutral
GlobeNewsWire
about one month ago
– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 –
More SELLAS Life Sciences Group, Inc. News

Company Profile

SELLAS Life Sciences Group, Inc. engages in the development and commercialization of immunotherapeutics for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Head office United States
CEO Angelos Stergiou
Employees 15
Founded 2006
Website www.sellaslifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today